TELA Bio Revenue Jumps 28% Amid Narrowing Losses

TL;DR

**TELA Bio is growing revenue fast and cutting losses, making it a strong buy for growth-focused investors.**

AI Summary

TELA Bio, Inc. reported a significant increase in revenue for the three months ended June 30, 2025, reaching $19.5 million, up from $15.2 million in the prior year, representing a 28.3% growth. For the six months ended June 30, 2025, total revenue was $37.1 million, a 27.5% increase from $29.1 million in the same period of 2024. The net loss for the three months ended June 30, 2025, improved to $7.8 million from $9.1 million in the prior year, while the net loss for the six months ended June 30, 2025, was $16.1 million, an improvement from $18.2 million in 2024. The company's gross profit margin remained strong at 70.4% for the three months and 70.1% for the six months ended June 30, 2025. Key business changes include continued strong sales of Ovitex and Ovitex PRS products, which contributed significantly to revenue growth. Risks include ongoing net losses and the need for future capital, as the accumulated deficit reached $245.8 million as of June 30, 2025. The strategic outlook focuses on expanding market penetration for its soft tissue reconstruction products.

Why It Matters

TELA Bio's robust revenue growth of 28.3% for the quarter and 27.5% year-to-date signals strong market acceptance for its Ovitex and Ovitex PRS products, which is crucial for investors looking for growth in the medical device sector. The narrowing net losses, from $9.1 million to $7.8 million quarterly, suggest improved operational efficiency and a potential path to profitability, which could attract new investors. For employees, this growth indicates job security and potential expansion opportunities within the company. In a competitive market for soft tissue reconstruction, TELA Bio's performance demonstrates its ability to gain market share, potentially impacting competitors like Integra LifeSciences and Allergan.

Risk Assessment

Risk Level: medium — Despite strong revenue growth, TELA Bio reported an accumulated deficit of $245.8 million as of June 30, 2025, and continues to incur net losses, with a $7.8 million loss for the quarter. This indicates a reliance on future capital raises, which could dilute existing shareholder value. The company's ability to achieve profitability remains a key uncertainty.

Analyst Insight

Investors should consider TELA Bio for its significant revenue growth and improving net loss figures, but monitor its cash burn and path to profitability closely. A long position could be warranted for those comfortable with growth-stage medical device companies, but be aware of potential future equity raises.

Financial Highlights

debt To Equity

N/A

revenue

$19.5M

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$7.8M

eps

N/A

gross Margin

70.4%

cash Position

N/A

revenue Growth

+28.3%

Revenue Breakdown

Key Numbers

• $19.5M — Q2 2025 Revenue (Up 28.3% from $15.2M in Q2 2024, indicating strong product demand.)
• $37.1M — H1 2025 Revenue (Increased 27.5% from $29.1M in H1 2024, showing consistent growth.)
• $7.8M — Q2 2025 Net Loss (Improved from $9.1M in Q2 2024, signaling progress towards profitability.)
• $16.1M — H1 2025 Net Loss (Reduced from $18.2M in H1 2024, demonstrating better cost management.)
• 70.4% — Q2 2025 Gross Profit Margin (Strong margin indicating efficient production and pricing power.)
• $245.8M — Accumulated Deficit (As of June 30, 2025, highlighting the need for future capital.)

Key Players & Entities

• TELA Bio, Inc. (company) — filer of the 10-Q
• $19.5 million (dollar_amount) — total revenue for Q2 2025
• $15.2 million (dollar_amount) — total revenue for Q2 2024
• 28.3% (percentage) — revenue growth for Q2 2025
• $37.1 million (dollar_amount) — total revenue for H1 2025
• $29.1 million (dollar_amount) — total revenue for H1 2024
• $7.8 million (dollar_amount) — net loss for Q2 2025
• $9.1 million (dollar_amount) — net loss for Q2 2024
• $245.8 million (dollar_amount) — accumulated deficit as of June 30, 2025
• Ovitex (company) — key product contributing to revenue

FAQ

Risk Factors

• Accumulated Deficit and Need for Capital [high — financial]: The company has an accumulated deficit of $245.8 million as of June 30, 2025. This indicates a history of net losses and highlights the ongoing need for future capital to fund operations and growth initiatives.
• Continued Net Losses [medium — financial]: Despite revenue growth and improved gross margins, TELA Bio continues to report net losses. The net loss for Q2 2025 was $7.8 million, and for H1 2025 was $16.1 million. Sustained losses raise concerns about long-term profitability.
• Market Penetration Challenges [medium — operational]: The strategic outlook focuses on expanding market penetration for its soft tissue reconstruction products. Achieving this expansion may face challenges related to competition, adoption rates, and sales force effectiveness.
• Product Approval and Compliance [medium — regulatory]: As a medical device company, TELA Bio is subject to stringent regulatory oversight from bodies like the FDA. Any delays in product approvals, recalls, or compliance issues could significantly impact revenue and operations.

Industry Context

TELA Bio operates in the competitive medical device market, specifically focusing on soft tissue reconstruction. The industry is characterized by innovation, regulatory scrutiny, and the need for strong clinical evidence to support product adoption by healthcare providers.

Regulatory Implications

As a medical device manufacturer, TELA Bio is subject to rigorous FDA regulations for product development, manufacturing, and marketing. Compliance with these regulations is critical, and any adverse findings or delays in approvals can significantly impact the company's ability to generate revenue and grow.

What Investors Should Do

1. Monitor cash burn and future financing needs.
2. Evaluate the sustainability of gross margins.
3. Track market penetration and adoption of Ovitex products.

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the Q2 and H1 2025 financial results, showing revenue growth and improved net loss.
• 2025-08-11: 10-Q Filing Date — Public disclosure of the company's financial performance and condition for the period ending June 30, 2025.

Glossary

Accumulated Deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates the company's historical profitability and its reliance on external funding to cover losses, with TELA Bio at $245.8 million as of June 30, 2025.)

Gross Profit Margin

The percentage of revenue that exceeds the cost of goods sold. (Measures the company's pricing power and production efficiency. TELA Bio maintained a strong margin of 70.4% in Q2 2025.)

Ovitex

A proprietary mesh product line offered by TELA Bio for soft tissue reconstruction. (A key revenue driver for the company, showing strong sales performance contributing to overall revenue growth.)

Ovitex PRS

A specific product within TELA Bio's Ovitex line, likely tailored for particular surgical applications. (Another significant contributor to TELA Bio's revenue growth, indicating successful market adoption.)

Year-Over-Year Comparison

TELA Bio demonstrated robust revenue growth in the first half of 2025, with Q2 revenue up 28.3% year-over-year to $19.5 million and H1 revenue up 27.5% to $37.1 million. The company also showed improvement in its net loss, which narrowed from $9.1 million in Q2 2024 to $7.8 million in Q2 2025, and from $18.2 million in H1 2024 to $16.1 million in H1 2025. Gross profit margins remained strong and consistent at over 70%. No new significant risks were highlighted, but the existing risk of accumulated deficit and need for capital remains prominent.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share TELA The Nasdaq

Filing Documents

• tela-20250630x10q.htm (10-Q) — 1366KB
• tela-20250630xex3d1.htm (EX-3.1) — 8KB
• tela-20250630xex10d1.htm (EX-10.1) — 17KB
• tela-20250630xex10d2.htm (EX-10.2) — 78KB
• tela-20250630xex31d1.htm (EX-31.1) — 12KB
• tela-20250630xex31d2.htm (EX-31.2) — 12KB
• tela-20250630xex32d1.htm (EX-32.1) — 7KB
• tela-20250630xex32d2.htm (EX-32.2) — 7KB
• 0001558370-25-011052.txt ( ) — 6019KB
• tela-20250630.xsd (EX-101.SCH) — 35KB
• tela-20250630_cal.xml (EX-101.CAL) — 52KB
• tela-20250630_def.xml (EX-101.DEF) — 136KB
• tela-20250630_lab.xml (EX-101.LAB) — 374KB
• tela-20250630_pre.xml (EX-101.PRE) — 259KB
• tela-20250630x10q_htm.xml (XML) — 975KB

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 4 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 31 Item 4.

Controls and Procedures

Controls and Procedures 32

OTHER INFORMATION

PART II OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 32 Item 1A.

Risk Factors

Risk Factors 32 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities 32 Item 3. Defaults Upon Senior Securities 32 Item 4. Mine Safety Disclosures 32 Item 5. Other Information 33 Item 6. Exhibits 33

Signatures

Signatures 34 1 Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this "Quarterly Report") and the documents incorporated by reference herein contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, we may, through our officers and other authorized representatives, make certain forward-looking statements in publicly released materials, both written and oral, including statements contained in filings with the Securities and Exchange Commission, press releases, and our communications with our stockholders. Forward-looking statements are neither statements of historical facts nor assurances of future performance, but instead discuss the future of our business, operations, future financial performance, future financial condition, plans, anticipated growth strategies, anticipated or perceived trends in our business, the industry in which we operate or the broader economy, and other objectives of management. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "design," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "positioned," "potential," "seek," "should," "target," "will," "would," the negative of such terms, and other similar expressions although not all forward-looking statements contain these identifying words. You should understand that the following important factors could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in our forward-looking statements: estimates regarding future results of operations, financial position, research and development costs, capital requirements and our needs for additional financing; the commercial success and degree of market acceptance of our products; the introduction of

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements TELA Bio, Inc. Consolidated Balance Sheets (In thousands, except share and per share amounts) (Unaudited) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 34,977 $ 52,670 Accounts receivable, net of allowances of $ 263 and $ 275 11,236 10,098 Inventory 11,371 12,781 Prepaid expenses and other current assets 3,161 2,522 Total current assets 60,745 78,071 Property and equipment, net 2,167 2,341 Intangible assets, net 1,549 1,739 Right-of-use assets 1,616 1,738 Other long-term assets 1,131 2,276 Deferred tax asset, net 64 140 Restricted cash 265 265 Total assets $ 67,537 $ 86,570 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,741 $ 2,147 Accrued expenses and other current liabilities 13,987 13,451 Current portion of long-term debt 3,333 — Total current liabilities 19,061 15,598 Longterm debt 38,051 41,124 Other longterm liabilities 1,241 1,390 Total liabilities 58,353 58,112 Stockholders' equity: Preferred stock; $ 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding — — Common stock; $ 0.001 par value: 200,000,000 shares authorized; 39,584,178 and 39,395,712 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 40 39 Additional paid-in capital 388,968 387,059 Accumulated other comprehensive income 93 90 Accumulated deficit ( 379,917 ) ( 358,730 ) Total stockholders' equity 9,184 28,458 Total liabilities and stockholders' equity $ 67,537 $ 86,570 See accompanying notes to unaudited interim consolidated financial statements. 4 Table of Contents TELA Bio, Inc. Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts) (Unaudited) Three months ended June 30, Six months ended June 30, 2025 202

View Full Filing

View this 10-Q filing on SEC EDGAR